Verve Therapeutics Inc (VERV)
6.26
+0.04
(+0.64%)
USD |
NASDAQ |
Apr 26, 10:26
Verve Therapeutics Enterprise Value: -103.84M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | -103.84M |
| April 24, 2024 | -73.74M |
| April 23, 2024 | -48.65M |
| April 22, 2024 | -46.14M |
| April 19, 2024 | -68.72M |
| April 18, 2024 | -67.05M |
| April 17, 2024 | -60.36M |
| April 16, 2024 | -26.91M |
| April 15, 2024 | -12.69M |
| April 12, 2024 | 11.56M |
| April 11, 2024 | 50.86M |
| April 10, 2024 | 45.84M |
| April 09, 2024 | 107.72M |
| April 08, 2024 | 78.45M |
| April 05, 2024 | 88.49M |
| April 04, 2024 | 101.87M |
| April 03, 2024 | 104.37M |
| April 02, 2024 | 71.76M |
| April 01, 2024 | 445.54M |
| March 28, 2024 | 486.51M |
| March 27, 2024 | 478.99M |
| March 26, 2024 | 445.54M |
| March 25, 2024 | 476.48M |
| March 22, 2024 | 460.59M |
| March 21, 2024 | 480.66M |
| Date | Value |
|---|---|
| March 20, 2024 | 494.88M |
| March 19, 2024 | 463.94M |
| March 18, 2024 | 489.02M |
| March 15, 2024 | 530.83M |
| March 14, 2024 | 513.27M |
| March 13, 2024 | 575.15M |
| March 12, 2024 | 540.03M |
| March 11, 2024 | 581.84M |
| March 08, 2024 | 626.99M |
| March 07, 2024 | 625.32M |
| March 06, 2024 | 636.19M |
| March 05, 2024 | 642.05M |
| March 04, 2024 | 700.58M |
| March 01, 2024 | 738.21M |
| February 29, 2024 | 801.76M |
| February 28, 2024 | 877.85M |
| February 27, 2024 | 842.73M |
| February 26, 2024 | 583.51M |
| February 23, 2024 | 500.73M |
| February 22, 2024 | 489.86M |
| February 21, 2024 | 473.97M |
| February 20, 2024 | 468.12M |
| February 16, 2024 | 449.03M |
| February 15, 2024 | 464.61M |
| February 14, 2024 | 421.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-103.84M
Minimum
Apr 25 2024
3.133B
Maximum
Sep 10 2021
964.32M
Average
717.55M
Median
Enterprise Value Benchmarks
| Acorda Therapeutics Inc | 157.10M |
| Eli Lilly and Co | 711.57B |
| Intellia Therapeutics Inc | 1.012B |
| Beam Therapeutics Inc | 573.93M |
| Gritstone Bio Inc | 35.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.35M |
| Revenue (Quarterly) | 5.144M |
| Total Expenses (Quarterly) | 59.09M |
| EPS Diluted (Quarterly) | -0.69 |
| Profit Margin (Quarterly) | -940.0% |
| Earnings Yield | -49.84% |
| Normalized Earnings Yield | -49.84 |